ONCOCLíNICA, a specialized company in the health sector, provided an accounting loss of $ 759 million in the fourth quarter of 2024, which reflected a profit of $ 87 million in the same period from 2023.
Despite the negative result, the CEO of the company, Bruno Ferrari, explains that the damage is “just an account, not the treasurer, the result of a weakness From the company.
According to Ferrari, operational, the company made a profit more than $ 100 million.
actually Profit before interest, taxes, depreciation and extinguishing (EBITDA) The total rate of $ 272 million, with a slight increase of 0.2 % in comparison between the quarters.
In addition, CAPEX (capital expenses) dramatically decreased from more than $ 20 million in the fourth quarter of 2023 to $ 1.5 million in the same period from 2024.
Focus on reducing the leverage and generating money
One of the points highlighted by market analysts is the onclinicas effort to reduce their influence. Ferrari explains that part of this leverage is the result of the company’s acquisition and expansion operations, which have been stumbled from the public subscription.
The company adopted a new strategy last year, focusing on operational efficiency and cash generation.
“What do we do? Look at home, costs cost effectiveness, and brings operational efficiency, yet we can reduce our debts despite the increase in interest rates,” says CEO.
Challenges and opportunities in the oncology sector
Ferrari notes that the health sector faced major challenges last year, with civil sources due to increased costs, the reaction of the epidemic remains.
However, it indicates that the incidence of cancer tends to increase with the aging of the population, which represents a challenge and opportunity for the company.
Oncoclinicas has expanded the scope of its services, which covers the entire cancer patient’s journey, from the diagnosis to the final discharge.
This includes the integration of hospital services, surgeries, diagnoses and most complicated procedures such as marrow transplants.
Ferrari emphasizes the importance of cost effectiveness and adopting new technologies in oncology.
“The important thing here is to provide the appropriate treatment for this appointed patient in time, for the time specified, to be pushed properly in exchange for that and maintain this entire system balanced,” the CEO concludes.
